Roberto S Accolla Selected Research

Therapeutic Uses

7/2010	Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.
1/2005	Sequential immunogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roberto S Accolla Research Topics

Disease

24	Neoplasms (Cancer) 10/2023 - 05/2003
4	Adenocarcinoma 06/2009 - 05/2003
3	Infections 01/2018 - 01/2017
3	Neuroblastoma 07/2010 - 10/2003
2	Glioblastoma (Glioblastoma Multiforme) 01/2023 - 01/2021
2	Leukemia 01/2022 - 01/2017
2	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2021 - 01/2016
2	Necrosis 03/2013 - 07/2010
2	Fibrosarcoma 04/2006 - 05/2003
2	Carcinoma (Carcinomatosis) 04/2006 - 05/2003
1	Inflammation (Inflammations) 10/2023
1	Pathologic Processes 10/2023
1	Frailty 09/2023
1	Carcinogenesis 01/2022
1	Hepatocellular Carcinoma (Hepatoma) 01/2022
1	Neglected Diseases 01/2017
1	Tropical Spastic Paraparesis (Tropical Spastic Paraplegia) 01/2017
1	Pancreatic Neoplasms (Pancreatic Cancer) 10/2014
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2012
1	T-Cell Leukemia (Leukemia, T Cell) 08/2006
1	Virus Diseases (Viral Diseases) 04/2005

Drug/Important Bio-Agent (IBA)

10	Histocompatibility Antigens Class IIIBA 10/2023 - 05/2003
8	Neoplasm Antigens (Tumor Antigens)IBA 10/2023 - 06/2006
6	Proteins (Proteins, Gene)FDA Link 10/2023 - 04/2006
6	MHC class II transactivator proteinIBA 01/2023 - 05/2003
6	VaccinesIBA 01/2023 - 06/2006
5	AntigensIBA 01/2023 - 07/2012
4	Cancer VaccinesIBA 01/2022 - 03/2013
3	Peptides (Polypeptides)IBA 01/2022 - 05/2003
3	Trans-Activators (Trans-Acting Factor)IBA 01/2019 - 08/2006
3	Melphalan (Alkeran)FDA LinkGeneric 03/2013 - 04/2006
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2010 - 04/2006
2	Messenger RNA (mRNA)IBA 09/2023 - 10/2003
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 01/2012
2	CytokinesIBA 01/2018 - 04/2005
2	DNA (Deoxyribonucleic Acid)IBA 01/2012 - 12/2007
2	Therapeutic UsesIBA 07/2010 - 01/2005
2	Interleukin-12 (IL 12)IBA 12/2007 - 01/2005
2	Fibronectins (Fibronectin)IBA 12/2007 - 04/2006
1	NLR ProteinsIBA 10/2023
1	NucleotidesIBA 10/2023
1	COVID-19 VaccinesIBA 09/2023
1	BNT162 VaccineIBA 09/2023
1	Viral ProteinsIBA 01/2022
1	EpitopesIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 10/2020
1	Protein Subunit VaccinesIBA 01/2019
1	Histocompatibility Antigens Class IIBA 01/2019
1	AntibodiesIBA 01/2019
1	env Gene ProductsIBA 01/2018
1	MitogensIBA 01/2018
1	Staphylococcal Protein A (Protein A)IBA 01/2017
1	Liposomes (Liposome)IBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Clodronic Acid (Clodronate)IBA 01/2017
1	factor AIBA 07/2015
1	ElementsIBA 03/2013
1	Fluorescent Dyes (Fluorescent Probes)IBA 01/2012
1	PerforinIBA 01/2012
1	Cell ExtractsIBA 01/2012
1	Interleukin-2 (IL2)IBA 07/2010
1	nuclear factor YIBA 08/2006
1	Interleukin-15 (Interleukin 15)IBA 01/2005
1	3-hydroxy-5-estrane-17-carbonitrile (ACN)IBA 10/2003
1	Complementary DNA (cDNA)IBA 10/2003
1	Interferon-gamma (Interferon, gamma)IBA 10/2003

Therapy/Procedure

10	Immunotherapy 10/2023 - 12/2007
5	Therapeutics 03/2013 - 01/2005
2	Radiotherapy 03/2013 - 07/2012
2	Drug Therapy (Chemotherapy) 03/2013 - 07/2012
1	Aftercare (After-Treatment) 12/2007